Literature DB >> 7739691

Interferon and hepatitis C.

N Terrault, T Wright.   

Abstract

Mesh:

Substances:

Year:  1995        PMID: 7739691     DOI: 10.1056/NEJM199506013322211

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  8 in total

1.  Interferon-alpha in hepatitis C. Dosage, costs and benefits.

Authors:  A Briggs; A Shiell
Journal:  Pharmacoeconomics       Date:  1996-09       Impact factor: 4.981

2.  Predictors and noninvasive identification of severe liver fibrosis in patients with chronic hepatitis C.

Authors:  Mohamed A Metwally; Claudia O Zein; Nizar N Zein
Journal:  Dig Dis Sci       Date:  2007-01-09       Impact factor: 3.199

Review 3.  Mixed cryoglobulinemia as a model of systemic vasculitis.

Authors:  F Dammacco; D Sansonno
Journal:  Clin Rev Allergy Immunol       Date:  1997       Impact factor: 8.667

4.  Screening asymptomatic people at high risk for hepatitis C. The case for.

Authors:  C A Seymour
Journal:  BMJ       Date:  1996-05-25

5.  Hepatitis C virus--a pathogen for all people.

Authors:  L Dove; T L Wright
Journal:  West J Med       Date:  1996-06

6.  Lymphoblastoid interferon alfa treatment in chronic hepatitis C.

Authors:  R Iorio; P Pensati; S Porzio; I Fariello; S Guida; A Vegnente
Journal:  Arch Dis Child       Date:  1996-02       Impact factor: 3.791

7.  High-dose interferon-alpha 2b for re-treatment of nonresponders or relapsing patients with chronic hepatitis C. A controlled randomized trial.

Authors:  H L Bonkovsky; B D Clifford; L J Smith; C Allan; B Banner
Journal:  Dig Dis Sci       Date:  1996-01       Impact factor: 3.199

8.  Update on recently approved treatments for hepatitis C.

Authors:  Daniel Chao; Gregory J Botwin; Timothy R Morgan
Journal:  Curr Treat Options Gastroenterol       Date:  2014-06
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.